PURPOSE: To develop an L-PG-based imaging probe suitable for assessing the degradation of L-PG in vivo. MATERIALS AND METHODS: Conjugates of L-PG and a near-infrared fluorescence (NIRF) dye, NIR813, were characterized with regard to quenching efficiency and degradability by cathepsin B (CB) and other proteases. The kinetics of L-PG-NIR813's degradation and its degradation in orthotopic human U87/TGL glioma in nude mice after intravenous injection was assessed using NIRF optical imaging (n = 3). RESULTS: The fluorescence signal from L-PG-NIR813 was efficiently quenched and activated at NIR813 loadings of 8-10%. Upon exposure to CB, the fluorescence intensity of L-PG-NIR813 increased 10-fold. L-PG-NIR813 was also degraded by another cysteine protease cathepsin L, but not by MMP-2, cathepsin E, cathepsin D, and plasmin. A selective CB inhibitor blocked the fluorescence activation. After intravenous injection, the degradation of L-PG-NIR813 was visualized primarily in the liver, which peaked at 4 h postinjection. Activation of L-PG-NIR813 but not D-PG-NIR813 was clearly seen in U87/TGL tumors. CONCLUSION: Our results indicate that L-PG-NIR813 may be used to monitor the in vivo degradation of L-PG-based polymeric drugs, and that this agent may prove useful in noninvasive imaging of protease activity, particularly that of cysteine proteases.
PURPOSE: To develop an L-PG-based imaging probe suitable for assessing the degradation of L-PG in vivo. MATERIALS AND METHODS: Conjugates of L-PG and a near-infrared fluorescence (NIRF) dye, NIR813, were characterized with regard to quenching efficiency and degradability by cathepsin B (CB) and other proteases. The kinetics of L-PG-NIR813's degradation and its degradation in orthotopic human U87/TGL glioma in nude mice after intravenous injection was assessed using NIRF optical imaging (n = 3). RESULTS: The fluorescence signal from L-PG-NIR813 was efficiently quenched and activated at NIR813 loadings of 8-10%. Upon exposure to CB, the fluorescence intensity of L-PG-NIR813 increased 10-fold. L-PG-NIR813 was also degraded by another cysteine protease cathepsin L, but not by MMP-2, cathepsin E, cathepsin D, and plasmin. A selective CB inhibitor blocked the fluorescence activation. After intravenous injection, the degradation of L-PG-NIR813 was visualized primarily in the liver, which peaked at 4 h postinjection. Activation of L-PG-NIR813 but not D-PG-NIR813 was clearly seen in U87/TGL tumors. CONCLUSION: Our results indicate that L-PG-NIR813 may be used to monitor the in vivo degradation of L-PG-based polymeric drugs, and that this agent may prove useful in noninvasive imaging of protease activity, particularly that of cysteine proteases.
Authors: Vladimir Ponomarev; Michael Doubrovin; Inna Serganova; Jelena Vider; Aleksander Shavrin; Tatiana Beresten; Anna Ivanova; Ludmila Ageyeva; Vilia Tourkova; Julius Balatoni; William Bornmann; Ronald Blasberg; Juri Gelovani Tjuvajev Journal: Eur J Nucl Med Mol Imaging Date: 2004-03-11 Impact factor: 9.236
Authors: Mei Tian; Xiaoxia Wen; Edward F Jackson; Chaan Ng; Rajesh Uthamanthil; Dong Liang; Juri G Gelovani; Chun Li Journal: Contrast Media Mol Imaging Date: 2011-01-06 Impact factor: 3.161
Authors: Julia Y Ljubimova; Tao Sun; Leila Mashouf; Alexander V Ljubimov; Liron L Israel; Vladimir A Ljubimov; Vida Falahatian; Eggehard Holler Journal: Adv Drug Deliv Rev Date: 2017-06-10 Impact factor: 15.470
Authors: Qing Ma; Dapeng Zhou; Elizabeth S DeLyria; Xiaoxia Wen; Wei Lu; Prakash Thapa; Chengwen Liu; Dan Li; Roland L Bassett; Willem W Overwijk; Patrick Hwu; Chun Li Journal: J Immunother Date: 2017-01 Impact factor: 4.456
Authors: Emerson C Perin; Mei Tian; Frank C Marini; Guilherme V Silva; Yi Zheng; Fred Baimbridge; Xin Quan; Marlos R Fernandes; Amir Gahremanpour; Daniel Young; Vincenzo Paolillo; Uday Mukhopadhyay; Agatha T Borne; Rajesh Uthamanthil; David Brammer; James Jackson; William K Decker; Amer M Najjar; Michael W Thomas; Andrei Volgin; Brian Rabinovich; Suren Soghomonyan; Hwan-Jeong Jeong; Jesse M Rios; David Steiner; Simon Robinson; Osama Mawlawi; Tinsu Pan; Jason Stafford; Vikas Kundra; Chun Li; Mian M Alauddin; James T Willerson; Elizabeth Shpall; Juri G Gelovani Journal: PLoS One Date: 2011-09-01 Impact factor: 3.240
Authors: Aristarchos Papagiannaros; Amit Kale; Tatyana S Levchenko; Dmitry Mongayt; William C Hartner; Vladimir P Torchilin Journal: Int J Nanomedicine Date: 2009-04-20